Biohaven Ltd. has teamed up with Ono Pharmaceutical in a big agreement.

Oct 15, 2026, 5:36 PM ETDealRead the original at SEC EDGAR

Good for BHVN

Biohaven is due $80 million when the deal closes and may receive a conditional $20 million plus royalties near 20% on sales in the licensed areas. Ono generally pays local development costs, but Biohaven keeps some work and costs, and Ono can end the deal; the promised payments still make this favorable.

BHVN · Biohaven Ltd.

AI read · Good for BHVN

The AI's read

The agreement promises Biohaven an initial payment and a share of sales in several Asian markets. Ono generally pays for development there, though Biohaven still has studies and some shared costs. The extra payment depends on test results and Ono choosing to continue, and Ono can end the deal. The initial payment and possible sales income make this favorable for Biohaven.

Get alerts for BHVN

Follow Biohaven Ltd. (BHVN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BHVN

Free on the App Store and Google Play, or on the web.